What is Ruvalcaba Syndrome

TL;DR: Ruvalcaba syndrome is an extremely rare genetic condition characterized by macrocephaly (an unusually large head), intestinal polyposis, and pigmented macules on the penis. It is now widely recognized as part of the PTEN hamartoma tumor syndrome (PHTS) spectrum, which involves mutations that lead to the overgrowth of various tissues throughout the body.

What are the primary features of Ruvalcaba syndrome?

Ruvalcaba syndrome, historically referred to as Ruvalcaba-Myhre-Smith syndrome, primarily affects the gastrointestinal tract, skin, and neurological development. Individuals with Ruvalcaba syndrome often present with hamartomatous polyps—benign growths—in the colon and rectum, which may lead to gastrointestinal bleeding or anemia. The condition is also marked by distinct physical features, including a large head circumference and dark, freckle-like spots (pigmented macules) on the glans penis, which are a hallmark clinical sign for diagnosis.

What causes Ruvalcaba syndrome?

Research indicates that Ruvalcaba syndrome is caused by mutations in the PTEN gene. This gene acts as a tumor suppressor, meaning it typically regulates cell division and prevents cells from growing too rapidly. When this gene is mutated, cells may grow and divide uncontrollably, leading to the formation of hamartomas (benign tumors) and the physical overgrowth patterns seen in patients. Because Ruvalcaba syndrome is part of the PHTS spectrum, it shares a genetic foundation with conditions like Cowden syndrome.

How is Ruvalcaba syndrome classified?

Clinically, Ruvalcaba syndrome is classified as a developmental disorder with a predisposition to tumor growth. Key clinical markers include:

• Macrocephaly (large head size) present from birth or early childhood.


• Intestinal polyposis, typically identified during gastrointestinal screenings.


• Pigmented macules on the penis (often appearing in childhood).


• Developmental delays or intellectual disability in some, though not all, individuals.


• Subcutaneous lipomas (fatty tissue tumors) occurring in various parts of the body.

How rare is this condition?

Ruvalcaba syndrome is exceptionally rare, with very few cases documented in medical literature. While exact global prevalence numbers are unavailable due to its rarity and historical overlap with other PHTS conditions, the DiseaseMaps community currently supports 24 individuals who have identified with this diagnosis. It affects both males and females, and because it is an autosomal dominant condition, a single copy of the mutated gene is sufficient to cause the syndrome.

Next steps

• Consult with a clinical geneticist to confirm the diagnosis through PTEN gene testing.


• Establish a surveillance plan with a gastroenterologist for regular colonoscopies to monitor polyps.


• Connect with others by joining the 24 members of the DiseaseMaps community for Ruvalcaba syndrome.


• Consult an oncologist or specialist familiar with PHTS to monitor for potential tumor development.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult a qualified healthcare professional for diagnosis and treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): PTEN hamartoma tumor syndrome.


• Orphanet: Rare disease database entries for PHTS spectrum disorders.


• OMIM (Online Mendelian Inheritance in Man): Entry #158350 (Ruvalcaba-Myhre-Smith syndrome).


• PubMed: Peer-reviewed clinical studies on PTEN-related hamartoma syndromes.